Moderna ( (MRNA) ) just unveiled an update.
Moderna announced its participation in the ESCMID 2025 Global Congress in Vienna, where it will present research on various infectious diseases, including COVID-19, influenza, RSV, CMV, norovirus, and mpox. The company will showcase twelve scientific presentations, emphasizing its extensive research in respiratory and emerging infectious diseases. This event highlights Moderna’s commitment to advancing mRNA technology and its impact on infectious disease treatment, reinforcing its position as a leader in the pharmaceutical industry.
More about Moderna
Moderna is a leader in the field of mRNA medicine, focusing on the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. The company is known for its rapid advancement in mRNA technology, which has led to the creation of one of the earliest and most effective COVID-19 vaccines.
YTD Price Performance: -40.21%
Average Trading Volume: 11,820,394
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.69B
Find detailed analytics on MRNA stock on TipRanks’ Stock Analysis page.